Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300950 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer
A Phase 2 study of Pancreas Cancer, sponsored by GlobeImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
- 20
- Study locations
NCT00300950 is a Phase 2 study of Pancreas Cancer that has completed, run by GlobeImmune. The registered enrollment target is 176 participants, below the 904-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00300950, a Phase 2 study of Pancreas Cancer, has completed, sponsored by GlobeImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
- 20
- Study locations
Study Summary
The GI-4000 therapeutic vaccine or placebo will be injected under the skin of post-resection, non-metastatic pancreas cancer patients. Patients will be monitored for recurrence as well as safety, and immune responses related to the injections.
Conditions Studied
Interventions
- DRUG Gemcitabine
- BIOLOGICAL GI-4000
Study Locations (20)
Texas
- Texas Oncology, PA - Dallas
- The Texas Cancer Center Dallas Southwest - Dallas
- Baylor College of Medicine - Houston
- South Texas Oncology & Hematology - San Antonio
- Tyler Cancer Center - Tyler
California
- Tower Cancer Research Foundation - Beverly Hills
- University of California San Diego - La Jolla
- UCLA Medical Center - Los Angeles
Tamil Nadu
- PSG Hospitals - Peelamedu, Coimbatore
- Sri Ramchandra Medical College & Research Institute - Ponur, Chennai
Alabama
- University of Alabama at Birmingham - Birmingham
District of Columbia
- Georgetown University Medical Center / Lombardi Cancer Center - Washington D.C.
Illinois
- Rush University Medical School - Chicago
Minnesota
- Minnesota Oncology Hematology, PA - Minneapolis
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2006-01 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00300950
The ClinicalTrials.gov registry entry for NCT00300950 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 904-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (81% lower). The listed sponsor is GlobeImmune, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreas Cancer appearing as the primary indexed condition, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00300950 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Texas, California, Tamil Nadu.
Frequently Asked Questions
What is clinical trial NCT00300950 about?
NCT00300950 is a clinical study titled "Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer". The GI-4000 therapeutic vaccine or placebo will be injected under the skin of post-resection, non-metastatic pancreas cancer patients. Patients will be monitored for recurrence as well as safety, and immune responses related to the injections.
What is the current status of trial NCT00300950?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2006-01. Estimated completion is 2015-02.
What conditions does trial NCT00300950 study?
This clinical trial studies the following conditions: Pancreas Cancer.
What interventions are being tested in trial NCT00300950?
The interventions under investigation include: Gemcitabine (DRUG), GI-4000 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00300950?
This trial is sponsored by GlobeImmune, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00300950 being conducted?
This trial has 20 study locations across Alabama, California, District of Columbia, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
-
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)
ACTIVE NOT RECRUITING · Phase 2
-
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.